The efficacy of supplementation with the novel medical food, Souvenaid, in patients with Alzheimer's disease: A systematic review and meta-analysis of randomized clinical trials

References

• Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet 2006;368:387–403. doi: 10.1016/S0140-6736(06)69113-7
   PubMed Web of Science ®Google Scholar
• Förstl H, Kurz A. Clinical features of Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci 1999;249:288–90. doi: 10.1007/PL00014176
   PubMed Web of Science ®Google Scholar
• Burns A, Jacoby R, Luthert P, Levy R. Cause of death in Alzheimer's disease. Age Ageing 1990;19:341–4. doi: 10.1093/ageing/19.5.341
   PubMed Web of Science ®Google Scholar
• Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement 2013;9(1):63–75. doi: 10.1016/j.jalz.2012.11.007
   PubMed Web of Science ®Google Scholar
• Bowirrat A, Friedland RP, Farrer L, Baldwin C, Korczyn A. Genetic and environmental risk factors for Alzheimer's disease in Israeli Arabs. J Mol Neurosci 2002;19:239–45. doi: 10.1007/s12031-002-0040-4
   PubMed Web of Science ®Google Scholar
• Hendrie HC, Hall KS, Ogunniyi A, Gao S. Alzheimer's disease, genes, and environment: the value of international studies. Can J Psychiatry 2004;49:92–9. doi: 10.1177/070674370404900203
   PubMed Web of Science ®Google Scholar
• Otaegui-Arrazola A, Amiano P, Elbusto A, Urdaneta E, Martínez-Lage P. Diet, cognition, and Alzheimer's disease: food for thought. Eur J Nutr 2014;53:1–23. doi: 10.1007/s00394-013-0561-3
   PubMed Web of Science ®Google Scholar
• Crichton GE, Bryan J, Murphy KJ. Dietary antioxidants, cognitive function and dementia—a systematic review. Plant Foods Hum Nutr 2013;68:279–92. doi: 10.1007/s11130-013-0370-0
   PubMed Web of Science ®Google Scholar
• Grodstein F, O'Brien J, Kang JH, Dushkes R, Cook NR, Okereke O, et al. Long-term multivitamin supplementation and cognitive function in men: a randomized trial. Ann Intern Med 2013;17:806–14.
   Google Scholar
• Savelkoul PJ, Janickova H, Kuipers AA, Hageman RJ, Kamphuis PJ, Dolezal V, et al. A specific multi-nutrient formulation enhances M1 muscarinic acetylcholine receptor responses in vitro. J Neurochem 2012;120:631–40. doi: 10.1111/j.1471-4159.2011.07616.x
   PubMed Web of Science ®Google Scholar
• Wurtman RJ, Cansev M, Sakamoto T, Ulus IH. Use of phosphatide precursors to promote synaptogenesis. Annu Rev Nutr 2009;29:59–87. doi: 10.1146/annurev-nutr-080508-141059
   PubMed Web of Science ®Google Scholar
• Pooler AM, Guez DH, Benedictus R, Wurtman RJ. Uridine enhances neurite outgrowth in nerve growth factor-differentiated pheochromocytoma cells. Neuroscience 2005;134:207–14. doi: 10.1016/j.neuroscience.2005.03.050
   PubMed Web of Science ®Google Scholar
• Sakamoto T, Cansev M, Wurtman RJ. Oral supplementation with docosahexaenoic acid and uridine-5′-monophosphate increases dendritic spine density in adult gerbil hippocampus. Brain Res 2007;1182:50–9. doi: 10.1016/j.brainres.2007.08.089
   PubMed Web of Science ®Google Scholar
• van Wijk N, Watkins CJ, Böhlke M, Maher TJ, Hageman RJ, Kamphuis PJ, et al. Plasma choline concentration varies with different dietary levels of vitamins B6, B12 and folic acid in rats maintained on choline-adequate diets. Br J Nutr 2012;107:1408–12. doi: 10.1017/S0007114511004570
   PubMed Web of Science ®Google Scholar
• de Wilde MC, Penke B, van der Beek EM, Kuipers AA, Kamphuis PJ, Broersen LM. Neuroprotective effects of a specific multi-nutrient intervention against Abeta42–induced toxicity in rats. J Alzheimers Dis 2011;27:327–39.
   PubMed Web of Science ®Google Scholar
• de Bruin NM, Kiliaan AJ, de Wilde MC, Broersen LM. Combined uridine and choline administration improves cognitive deficits in spontaneously hypertensive rats. Neurobiol Learn Mem 2003;80:63–79. doi: 10.1016/S1074-7427(03)00024-8
   PubMed Web of Science ®Google Scholar
• Ishrat T, Parveen K, Khan MM, Khuwaja G, Khan MB, Yousuf S, et al. Selenium prevents cognitive decline and oxidative damage in rat model of streptozotocin-induced experimental dementia of Alzheimer's type. Brain Res 2009;1281:117–27. doi: 10.1016/j.brainres.2009.04.010
   PubMed Web of Science ®Google Scholar
• Berr C, Arnaud J, Akbaraly TN. Selenium and cognitive impairment: a brief-review based on results from the EVA study. Biofactors 2012;38(2):139–44. doi: 10.1002/biof.1003
   PubMed Web of Science ®Google Scholar
• de Waal H, Stam CJ, Lansbergen MM, Wieggers RL, Kamphuis PJ, Scheltens P, et al. The effect of souvenaid on functional brain network organisation in patients with mild Alzheimer's disease: a randomised controlled study. PLoS One 2014;9(1):e86558. doi: 10.1371/journal.pone.0086558
   Google Scholar
• Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928. doi: 10.1136/bmj.d5928
   PubMed Web of Science ®Google Scholar
• Deeks JJ, Higgins JPT, Altman DG, editors. Chapter 16/16.1.3.2: imputing standard deviations for changes from baseline. In: Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated March 2011). The Cochrane Collaboration; 2011. Available from: www.cochrane-handbook.org. (accessed 15 May 2015).
   Google Scholar
• Review Manager (RevMan) [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
   Google Scholar
• Kamphuis PJ, Verhey FR, Olde Rikkert MG, Twisk JW, Swinkels SH, Scheltens P. Efficacy of a medical food on cognition in Alzheimer's disease: results from secondary analyses of a randomized, controlled trial. J Nutr Health Aging 2011;15:720–4. doi: 10.1007/s12603-011-0105-6
   PubMed Web of Science ®Google Scholar
• Kamphuis PJ, Verhey FR, Olde Rikkert MG, Twisk JW, Swinkels SH, Scheltens P. Effect of a medical food on body mass index and activities of daily living in patients with Alzheimer's disease: secondary analyses from a randomized, controlled trial. J Nutr Health Aging 2011;15:672–6. doi: 10.1007/s12603-011-0339-3
   PubMed Web of Science ®Google Scholar
• Olde Rikkert MG, Verhey FR, Blesa R, von Arnim CA, Bongers A, Harrison J, et al. Tolerability and safety of Souvenaid in patients with mild Alzheimer's disease: results of multi-center, 24–week, open-label extension study. J Alzheimers Dis 2015;44(2):471–80.
   PubMed Web of Science ®Google Scholar
• Pardini M, Serrati C, Guida S, Mattei C, Abate L, Massucco D, et al. Souvenaid reduces behavioral deficits and improves social cognition skills in frontotemporal dementia: a proof-of-concept study. Neurodegener Dis 2015;15(1):58–62. doi: 10.1159/000369811
   PubMed Web of Science ®Google Scholar
• Scheltens P, Kamphuis PJ, Verhey FR, Olde Rikkert MG, Wurtman RJ, Wilkinson D, et al. Efficacy of a medical food in mild Alzheimer's disease: a randomized, controlled trial. Alzheimers Dement 2010;6:1–10. doi: 10.1016/j.jalz.2009.10.003
   PubMed Web of Science ®Google Scholar
• Scheltens P, Twisk JW, Blesa R, Scarpini E, von Arnim CA, Bongers A, et al. Efficacy of Souvenaid in mild Alzheimer's disease: results from a randomized, controlled trial. J Alzheimers Dis 2012;31:225–36.
   PubMed Web of Science ®Google Scholar
• Shah RC, Kamphuis PJ, Leurgans S, Swinkels SH, Sadowsky CH, Bongers A, et al. The S-Connect study: results from a randomized, controlled trial of Souvenaid in mild-to-moderate Alzheimer's disease. Alzheimers Res Ther 2013;5(6):59. doi: 10.1186/alzrt224
   PubMed Web of Science ®Google Scholar
• Mueller SG, Schuff N, Yaffe K, Madison C, Miller B, Weiner MW. Hippocampal atrophy patterns in mild cognitive impairment and Alzheimer's disease. Hum Brain Mapp 2010;31:1339–47. doi: 10.1002/hbm.20934
   PubMed Web of Science ®Google Scholar
• Scheff SW, Price DA, Schmitt FA, Mufson EJ. Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment. Neurobiol Aging 2006;27:1372–84. doi: 10.1016/j.neurobiolaging.2005.09.012
   PubMed Web of Science ®Google Scholar
• Scheff SW, Price DA, Schmitt FA, Roberts KN, Ikonomovic MD, Mufson EJ. Synapse stability in the precuneus early in the progression of Alzheimer's disease. J Alzheimers Dis 2013;35:599–609.
   PubMed Web of Science ®Google Scholar
• Sun Y, Yin Q, Fang R, Yan X, Wang Y, Bezerianos A, et al. Disrupted functional brain connectivity and its association to structural connectivity in amnestic mild cognitive impairment and Alzheimer's disease. PLoS One 2014;9(5):e96505. doi: 10.1371/journal.pone.0096505
   Google Scholar
• O'Bryant SE, Lacritz LH, Hall J, Waring SC, Chan W, Khodr ZG, et al. Validation of the new interpretive guidelines for the clinical dementia rating scale sum of boxes score in the national Alzheimer's coordinating center database. Arch Neurol 2010;67:746–9.
   PubMed Web of Science ®Google Scholar
• Joffres C, Graham J, Rockwood K. Qualitative analysis of the clinician interview-based impression of change (Plus): methodological issues and implications for clinical research. Int Psychogeriatr 2000;12:403–13. doi: 10.1017/S1041610200006505
   PubMed Web of Science ®Google Scholar
• Li MM, Yu JT, Wang HF, Jiang T, Wang J, Meng XF, et al. Efficacy of vitamins B supplementation on mild cognitive impairment and Alzheimer's disease: a systematic review and meta-analysis. Curr Alzheimer Res 2014;11(9):844–52.
   PubMed Web of Science ®Google Scholar
• Farina N, Isaac MG, Clark AR, Rusted J, Tabet N. Vitamin E for Alzheimer's dementia and mild cognitive impairment. Cochrane Database Syst Rev 2012;14(11):CD002854.
   Google Scholar
• Freund-Levi Y, Eriksdotter-Jönhagen M, Cederholm T. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: Omega AD study: a randomized double-blind trial. Arch Neurol 2006;63(10):1402–8. doi: 10.1001/archneur.63.10.1402
   PubMed Web of Science ®Google Scholar
• Rijpma A, Meulenbroek O, Olde Rikkert MG. Cholinesterase inhibitors and add-on nutritional supplements in Alzheimer's disease: a systematic review of randomized controlled trials. Ageing Res Rev 2014;16:105–12. doi: 10.1016/j.arr.2014.06.002
   PubMed Web of Science ®Google Scholar
• Takeda A, Loveman E, Clegg A, Kirby J, Picot J, Payne E, et al. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease. Int J Geriatr Psychiatry 2006;21(1):17–28. doi: 10.1002/gps.1402
   PubMed Web of Science ®Google Scholar
• Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. Cochrane Database Syst Rev 2012;12:MR000033.
   PubMed Web of Science ®Google Scholar
• Freund-Levi Y, Visser PJ, Kivipelto M, Wieggers RL, Hartmann T, Soininen H. The LipiDiDiet study: rationale and study design. Alzheimers Dement 2012;8(4):P602. doi: 10.1016/j.jalz.2012.05.2093
   Google Scholar
• Nederlands Trial Register. LipiDiDiet Trial. Available from: http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=1705|. (accessed 20 Jun 2015).
   Google Scholar
• Jacobson MW, Delis DC, Bondi MW, Salmon DP. Do neuropsychological tests detect preclinical Alzheimer's disease: individual-test versus cognitive-discrepancy score analyses. Neuropsychology 2002;16:132–9. doi: 10.1037/0894-4105.16.2.132
   PubMed Web of Science ®Google Scholar